SCHEMBL17119640

SCHEMBL17119640

COC(=O)c1cnc(Cl)cc1Nc1ccncc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 1/20 0.43
▸ SMARCA4 P51532 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ AXL P30530 1/20 0.41
▸ TGFBR1 P36897 1/20 0.41
▸ CYP46A1 Q9Y6A2 1/20 0.41
▸ TYK2 P29597 2/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ KCNMA1 Q12791 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PABPC1 P11940 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18748194 0.87 CASP1 (0.47) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL17119642 0.85 GRIK1 (0.47) SMARCA2SMARCA4MAPTGAATYK2
SCHEMBL15131721 0.81 MAPT (0.50) KDM4EMAPTALOX15ALDH1A1GLA
SCHEMBL7569086 0.78 KDM4E (0.46) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL16879348 0.77 TGFBR1 (0.50) KDM4EALDH1A1GLAGAATGFBR1
SCHEMBL16964697 0.77 GAA (0.43) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL17134620 0.76 CLCN2 (0.41) KDM4EMAPTALDH1A1GAACYP46A1
SCHEMBL17156646 0.76 MAPT (0.42) KDM4EMAPTALDH1A1GLACYP46A1
SCHEMBL17156862 0.76 LMNA (0.45) KDM4EMAPTALDH1A1GAATGFBR1
SCHEMBL17134686 0.76 ALDH1A1 (0.47) MAPTALDH1A1GAATGFBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 SMARCA2 1880/4885SMARCA4 2029/4885KDM4E 2130/4885
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 SMARCA2 1880/4885SMARCA4 2029/4885KDM4E 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback